Avid Bioservices reported strong Q2 results, driven by growth in customer demand, achieving higher-than-expected revenues and margins, and generating operating cash flow and income from operations. The company is raising revenue guidance for fiscal 2021 from between $76 and $81 million to between $84 and $88 million.